Document is current

Article History

Received: 30 April 2022

Accepted: 31 July 2022

First Online: 23 August 2022

Declarations

:

: AA, BA, and SE report no disclosures. BF is supported by grant funding from the DOD (JW200215 and W81XWH1920013). He received additional support for research through the NIH/NINDS, NIH/NIBIB, and NSF. He receives speaking fees and consulting fees from UCB Pharma, and serves on the scientific advisory boards of Marinus, Inc and Sage Therapeutics. NG reports no disclosures. EJG is supported by grant funding from the NIH R01NS117904-01, is a consultant for UCB and co-founder (no financial relationship) of Intracranial Bioanalytics (IBA). LJH has received consultation fees for advising from Accure, Aquestive, Ceribell, Eisai, Marinus, Medtronic, Neurelis, Neuropace and UCB; royalties from Wolters-Kluwer for authoring chapters for UpToDate-Neurology, and from Wiley for co-authoring the book “Atlas of EEG in Critical Care”; and honoraria for speaking or running webinars from Neuropace, Natus, and UCB. PK reports no disclosures. VL reports no disclosures. JK is supported by grant funding through the University of Calgary, Office of Health and Medical Education Scholarship. PV is supported by grants from NIH and the State of California PV has received compensation for consultancy and speaker fees and expenses from Ceribell and consultancy and speaker fees from UCB Pharma. SFZ is supported by grant funding from the NIH K23NS114201 and the American Epilepsy Society (Infrastructure grant). She is a clinical neurophysiologist for Corticare. BR reports no disclosures. JC is a minority shareholder at iCE Neurosystems.